OBJECTIVE: The study goal was to determine the effectiveness of (1) multilevel temperature-controlled radiofrequency tissue ablation (TCRFTA) or (2) continuous positive airway pressure (CPAP) for the treatment of mild to moderate obstructive sleep apnea syndrome (OSAS). STUDY DESIGN AND METHODS: We conducted a randomized, placebo-controlled, 2-site trial, comparing TCRFTA (n = 30) and CPAP (n = 30) with sham-placebo (n = 30) using intention-to-treat analysis. RESULTS: Compared with pretreatment baseline, TCRFTA improved reaction time, OSAS-specific quality of life (QOL), and subjective sleepiness (all P < 0.05). Compared with sham-placebo, TCRFTA improved QOL, airway volume, apnea index, and respiratory arousal index (all P < 0.05). TCRFTA side effects and complications were mild, temporary, and similar to sham-placebo. CPAP improved QOL and sleepiness compared with baseline and QOL when compared with sham-placebo (all P < 0.05). Significant differences were not seen between TCRFTA and CPAP outcomes. CONCLUSION: TCRFTA and CPAP each improve QOL for mild-moderate OSAS patients. TCRFTA improvements may result from changes in airway volume, apnea index, and respiratory arousal index.
OBJECTIVE: The study goal was to determine the effectiveness of (1) multilevel temperature-controlled radiofrequency tissue ablation (TCRFTA) or (2) continuous positive airway pressure (CPAP) for the treatment of mild to moderate obstructive sleep apnea syndrome (OSAS). STUDY DESIGN AND METHODS: We conducted a randomized, placebo-controlled, 2-site trial, comparing TCRFTA (n = 30) and CPAP (n = 30) with sham-placebo (n = 30) using intention-to-treat analysis. RESULTS: Compared with pretreatment baseline, TCRFTA improved reaction time, OSAS-specific quality of life (QOL), and subjective sleepiness (all P < 0.05). Compared with sham-placebo, TCRFTA improved QOL, airway volume, apnea index, and respiratory arousal index (all P < 0.05). TCRFTA side effects and complications were mild, temporary, and similar to sham-placebo. CPAP improved QOL and sleepiness compared with baseline and QOL when compared with sham-placebo (all P < 0.05). Significant differences were not seen between TCRFTA and CPAP outcomes. CONCLUSION: TCRFTA and CPAP each improve QOL for mild-moderate OSAS patients. TCRFTA improvements may result from changes in airway volume, apnea index, and respiratory arousal index.
Authors: Richard J Schwab; Safwan M Badr; Lawrence J Epstein; Peter C Gay; David Gozal; Malcolm Kohler; Patrick Lévy; Atul Malhotra; Barbara A Phillips; Ilene M Rosen; Kingman P Strohl; Patrick J Strollo; Edward M Weaver; Terri E Weaver Journal: Am J Respir Crit Care Med Date: 2013-09-01 Impact factor: 21.405
Authors: Eric J Kezirian; Edward M Weaver; Mark A Criswell; Nico de Vries; B Tucker Woodson; Jay F Piccirillo Journal: Otolaryngol Head Neck Surg Date: 2011-02-14 Impact factor: 3.497
Authors: T Verse; R Bodlaj; R de la Chaux; A Dreher; C Heiser; M Herzog; W Hohenhorst; K Hörmann; O Kaschke; T Kühnel; N Mahl; J T Maurer; W Pirsig; K Rohde; A Sauter; M Schedler; R Siegert; A Steffen; B A Stuck Journal: HNO Date: 2009-11 Impact factor: 1.284
Authors: Susheel P Patil; Indu A Ayappa; Sean M Caples; R Joh Kimoff; Sanjay R Patel; Christopher G Harrod Journal: J Clin Sleep Med Date: 2019-02-15 Impact factor: 4.062
Authors: Karl A Franklin; Heidi Anttila; Susanna Axelsson; Thorarinn Gislason; Paula Maasilta; Kurt I Myhre; Nina Rehnqvist Journal: Sleep Date: 2009-01 Impact factor: 5.849